Express News | Creative Medical Technology Holdings, Inc. Advances FDA Cleared Adapt Clinical Trial With Positive Independent Review, Validating the Safety and Potential of Celz-201 for Chronic Lower Back Pain Treatment
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial With Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
Creative Medical Technology Holdings Third Quarter 2024 Earnings: US$0.75 Loss per Share (Vs US$1.02 Loss in 3Q 2023)
Creative Medical Technology | 10-Q: Q3 2024 Earnings Report
Creative Medical Technology Files to Sell 837,104 Shares of Common for Holders
Express News | Creative Medical Technology Files Patent For "AI Enhanced Real-Time Biological Optimization And Health Monitoring For Space Travel"
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Express News | Creative Medical Technology Holdings Inc - Company to Issue Warrants for 837,104 Shares at $4.42 per Share
Express News | Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Express News | Creative Medical Technology Holdings Inc Files for Mixed Shelf of up to $50 Mln - SEC Filing
Top Premarket Gainers
Creative Medical Technology | 10-Q: Q2 2024 Earnings Report
Express News | Creative Medical Technology Holdings Develops AI-Driven Diagnostic And Treatment Program For Biologic And Chemical Exposure
Express News | Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing Its Validated Ipsc Personalized Medicine Program
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
Express News | Creative Medical Technology Holdings: Sees Sufficient Funds to Meet Operating Costs, Capital Expenditure Requirements Through at Least Q2 2025
Roth MKM Maintains Creative Medical Technology(CELZ.US) With Buy Rating, Maintains Target Price $30
Express News | Creative Medical Technology Generated Human Induced Pluripotent Stem Cells IPSC-derived Islet Cells That Produce Human Insulin
Express News | Creative Medical: Successfully Generated Human Ipsc-Derived Islet Cells That Produce Human Insulin